Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Infographic: Are data blind spots putting your launch at risk?

July 16, 2026 |  

Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize opportunities, and optimize commercial strategy.​

InConcert™ brings together omnichannel, field, clinical, and predictive insights in a single decision-making environment – helping commercial teams make smarter, faster decisions backed by Intelligent Commercialization™.

- PMLiVE

Discover how InConcert™ supports commercial launch planning​

If you’re looking for a quick, easy-to-understand overview of InConcert™, this one-page guide is the perfect place to start.​

In just a few minutes, you’ll discover:​

  • The commercial challenge the solution is designed to solve.​
  • How it enables intelligent launch planning.​
  • The four intelligence capabilities that power InConcert™.​
  • The value it delivers for commercial and launch teams.​
  • How it helps organizations make more informed launch decisions.​

Whether you’re exploring InConcert™ for the first time or introducing it to key stakeholders, this concise overview explains everything you need to know – all on a single page.

Download now. 

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

How we elevated HCP market research engagement and insights using AI avatars for an immersive experience

Our client required an effective strategy for promoting discussions about self-paid vaccines with healthcare professionals (HCPs) during patient consultations. The conventional method of conducting market research would typically only deliver…

How we provided comprehensive real-world patient data for PAH using Therapy Watch, our syndicated market tracking solution

PAH is a specific type of pulmonary hypertension, which is a rare condition treated primarily in specialized centers. Our client needed to gain a comprehensive understanding of PAH patients, such…

The risk of replicating social bias in synthetic patient data – The need for human intelligence partnered with AI

Authored by Paul Reed and Anabelle Gall

Latest European developments and new talent at Research Partnership

Angela Duffy has been appointed as Managing Director for our European based ad hoc research teams. Angela has been an integral part of Research Partnership for 19 years, witnessing its…

New syndicated report – Living with Ulcerative Colitis 2024

Living with Ulcerative Colitis (UC) is a new syndicated patient report that presents valuable insights into the unmet needs and the burden experienced by patients living with UC. The report…

Webcast: AI in MRX: Harnessing the power of AI + people

Artificial intelligence (AI) in market research has surged in recent years, with a flow of innovative tools and techniques which have the potential to revolutionize the landscape. But to unlock…

Navigating challenges of MedTech research with rare-disease patients

Authored by: Tom Donnelly, MedTech Director and Amanda Pirraglia, Associate Director. Published in Quirk’s Magazine.

Product launch: What market research when?

Get the insights you need, when you need them, for your product launch planning

Therapy Watch launches new tracker covering Alzheimer’s Disease

The new Therapy Watch Alzheimer’s Disease tracker has recently launched in Germany, Japan and the US, with planned expansion into the remaining key European markets throughout 2024.

Therapy Watch launches new tracker covering pulmonary arterial hypertension (PAH)

Therapy Watch Pulmonary Arterial Hypertension (PAH) is launching in the US market, with expansion into other geographies including Europe in 2024.